Overview

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

Status:
NOT_YET_RECRUITING

Trial end date:
2030-08-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of \[177Lu\]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.

Phase:

PHASE2

Details

Lead Sponsor:

RTOG Foundation, Inc.

Collaborator:

Novartis Pharmaceuticals

Treatments:

Bevacizumab
Everolimus
Hydroxyurea
lutetium Lu 177 dotatate
Sunitinib